Navigation Links
Micell Technologies Reports Preclinical Data for MiStent™ Drug-Eluting Coronary Stent to be Presented at EuroPCR
Date:5/11/2011

DURHAM, N.C., May 11, 2011 /PRNewswire/ -- Micell Technologies, Inc. today announced that positive preclinical data will be presented at the EuroPCR conference in Paris, France on May 18, 2011 in a presentation titled, "MiStent DES: A Novel Third Generation DES with a Fully-absorbable Coating and Enhanced Drug Delivery Capabilities." The MiStent Drug-Eluting Coronary Stent System ("MiStent DES") is an ultra-thin, advanced alloy drug-eluting stent distinguished by a rapid-absorbing drug/polymer coating formulation.

In a porcine coronary model, data show continuous and controlled release of sirolimus, with the MiStent DES coating being eliminated from the stent within 45 to 60 days, and fully absorbed in the tissue by 90 days following implant. Preclinical studies additionally demonstrated a positive indication of safety with lower inflammation observed from the MiStent DES compared to the bare metal Abbott MULTI-LINK Vision™ Coronary Stent at 30 and 90 days in the challenging overlapping stents implant configuration.

James B. McClain, Ph.D., Senior Vice President of Micell, said, "Micell is uniting well-known DES stent components with a proprietary coating process to produce a fundamentally different DES. Our preclinical studies demonstrate a markedly consistent drug delivery profile with controlled, linear release of therapeutic levels of drug."

Clinical trials of the MiStent DES include DESSOLVE I, a study of 30 patients with documented stable or unstable angina pectoris or ischemia, which completed enrollment earlier this year. The primary endpoint is in-stent late lumen loss, as measured with angiography in treated de novo lesions ranging in diameter from 2.5 to 3.5 mm and amenable to treatment with a maximum 23 mm long stent. DESSOLVE II is an ongoing multi-center study of approximately 270 patients with documented stable or unstable angina pectoris or ischemia. The primary endpoint is superiority of MiStent DES in minimiz
'/>"/>

SOURCE Micell Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Micell Technologies Rapid Absorption Polymer DES System to be Presented at CRT 2009
2. Micell Forges Strategic Agreement to Develop Advanced Drug-Eluting Stents and Balloons
3. The Micell Rapid Absorption Polymer DES System to be Presented at TCT 2008
4. Terumo Americas Holding, Inc., Agrees to Acquire Harvest Technologies Corporation, a Leader in the Development of Point-of-Care Cellular Therapy
5. BioSpecifics Technologies Corp. Reports First Quarter 2011 Financial Results
6. Netsmart Technologies Names Michael Valentine as Chief Executive Officer
7. Caliper Owners Group and Investor Meeting to Highlight Technologies Enabling Personalized Medicine
8. Reportlinker Adds Biomarkers: Technologies and Global Markets
9. Reportlinker Adds Medical Enzymes: Technologies and Global Markets
10. Life Technologies Names Dr. Ora Hirsch Pescovitz to its Board of Directors
11. China Green Material Technologies, Inc. Announces Change of Auditor to Marcum Bernstein & Pinchuk LLP
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... , July 23, 2014  AuraSense Therapeutics, ... as gene regulatory and immunotherapeutic agents, announced ... joined AuraSense Therapeutics, executive leadership team as ... Prior to joining AuraSense Therapeutics, Mr. ... Financial Officer of Cellular Dynamics International Inc., ...
(Date:7/23/2014)... July 23, 2014 StemGenex® , ... in the US aimed at improving the lives of ... clinical study for Parkinson’s disease. StemGenex believes that ... cell therapy are paramount when providing care to patients ... makes stem cell therapy accessible to the millions of ...
(Date:7/23/2014)... , July 23, 2014 ... ), the global specialty biopharmaceutical company, and ArmaGen, ... a worldwide licensing and collaboration agreement for AGT-182, ... potential treatment of both the central nervous system ... syndrome (MPS II). This collaboration strengthens Shire,s rare ...
(Date:7/23/2014)... Plainsboro, N.J. (PRWEB) July 23, 2014 ... Lineberger Comprehensive Cancer Center has joined its Strategic ... the Strategic Alliance Partnership program, UNC Lineberger will ... team to raise awareness of its cutting-edge research ... Experts from UNC Lineberger will work with OncLive ...
Breaking Biology Technology:AuraSense Therapeutics Appoints Biotechnology Veteran David S. Snyder as Chief Financial Officer 2StemGenex® Gives Hope to Parkinson’s Patients through New Stem Cell Clinical Study 2StemGenex® Gives Hope to Parkinson’s Patients through New Stem Cell Clinical Study 3Shire Enters Strategic Licensing and Collaboration Agreement With ArmaGen 2Shire Enters Strategic Licensing and Collaboration Agreement With ArmaGen 3Shire Enters Strategic Licensing and Collaboration Agreement With ArmaGen 4Shire Enters Strategic Licensing and Collaboration Agreement With ArmaGen 5OncLive Expands Its Strategic Alliance Partnership Program With the Addition of UNC Lineberger Comprehensive Cancer Center 2OncLive Expands Its Strategic Alliance Partnership Program With the Addition of UNC Lineberger Comprehensive Cancer Center 3
... YORK, April 24 The Children,s Hospital Foundation,the ... and,Royalty Pharma announced today that the Foundation has ... of RotaTeq(R) from and after October,1, 2007, to ... (Logo: http://www.newscom.com/cgi-bin/prnh/20061026/RPLOGO ), "With the ...
... provides 510(k) on examination gloves made from U.S.-sourced guayule ... with Type I latex allergy, MARICOPA, Ariz., April ... found to be safe for medical devices, received,510(k) clearance ... market,the first medical device made from guayule, a desert ...
... The Board of,Directors of Shire plc (LSE: ... company, announces today that Michael Rosenblatt M.D.,will join ... effect., Dr Rosenblatt is the Dean of ... previously Professor of Medicine at Harvard,Medical School and ...
Cached Biology Technology:Royalty Pharma Acquires Royalty Interest in RotaTeq(R) from The Children's Hospital Foundation for $182 Million 2Royalty Pharma Acquires Royalty Interest in RotaTeq(R) from The Children's Hospital Foundation for $182 Million 3FDA Clears First Medical Product Made From Yulex(R) Natural Rubber 2Dr Michael Rosenblatt Appointed Non-Executive Director at Shire 2Dr Michael Rosenblatt Appointed Non-Executive Director at Shire 3Dr Michael Rosenblatt Appointed Non-Executive Director at Shire 4
(Date:7/23/2014)... that has the entire country in its grip is affecting ... be responsible for the proliferation of a heat-loving amoeba commonly ... hot springs, which the drought has made warmer than usual ... an infection caused by this parasite after swimming in several ... of an individual and travels to the brain. Nose plugs ...
(Date:7/23/2014)... DC -- The planet,s soil releases about 60 billion ... is far more than that released by burning fossil ... This enormous release of carbon is balanced by carbon ... other plant matter, as well as by the underground ... have documented that rising temperatures increase the rate of ...
(Date:7/23/2014)... is commonly found in dead bodies and is ... death, referred to as the post mortem interval. A ... from Tamil Nadu is provided for the first ... generation of DNA barcoding. This study, significant in forensic ... Data Journal . , Chrysomya megacephala is ...
Breaking Biology News(10 mins):Diseases of another kind 2Climate change and the soil 2Dead body feeding larvae useful in forensic investigations 2
... Researchers have demonstrated a new imaging tool for tracking ... bloodstream, which could aid efforts to perfect their use ... have potential applications in drug delivery to treat diseases ... are created in the manufacturing process, metallic and semiconducting. ...
... such as sharks, tunas, swordfish, and marlins are becoming increasingly ... researchers. In half of the North Atlantic ... to a 90-per-cent decrease in top predators since the 1950s, ... according to a new study published online today in the ...
... RIVERSIDE, Calif. A team of scientists from the University ... in the United States, last seen in 1956, living in ... as "Cockerell,s Bumblebee," the bee was originally described in 1913 ... 16 specimens collected near the town of Cloudcroft, and one ...
Cached Biology News:'Label-free' imaging tool tracks nanotubes in cells, blood for biomedical research 2Marine predators in trouble: UBC researchers 2Scientists rediscover rarest US bumblebee 2Scientists rediscover rarest US bumblebee 3
Rat monoclonal [HK5.3] to B7 RP1 (Phycoerythrin) ( Abpromise for all tested applications). entrezGeneID: 23308 SwissProtID: O75144...
... with the HECT protein, E6-AP ... Evidence suggests that this E2 ... degradation of non-""N-end rule"" protein ... -acetylated proteins as well as ...
NANS Immunogen: NANS (NP_061819, 260 a.a. ~ 360 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
ANTI-RAT ADHESION MARKERS, CDs, CYTOKINES, ETC Rat ICAM PE - Mouse IgG1...
Biology Products: